Project Grant R43HL174201
- The National Science Foundation (NSF) has awarded a $455,718 Faculty Early Career Development (CAREER) Project Grant to Marquette University to develop a living, tissue-engineered heart valve substitute capable of growing with child recipients of congenital heart valve defects. The 5-year project, funded under the NSF Engineering program (CFDA 47.041), aims to create a durable, hydrodynamically functional heart valve using an origami-inspired design and patient-derived cells that can self-repair...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...
- Federal Grant Award Summary Vivita Technologies Inc. received a $496,255 Phase I Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through May 31, 2026. The award supports development and validation of the company's SPEAR Platform technology, which generates unfixed, immune-compatible xenogeneic biomaterials derived from porcine pericardium for...
- Federal Grant Award Summary Aptus, LLC received a $643,358 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2027. The grant funds development of an expandable pediatric pulmonary heart valve designed to address a critical clinical gap in treatment options for infants and children born with severe heart valve defects. The device incorporates a novel...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Peca Labs Inc. a Project Grant of $306,102 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period of August 1, 2025 through July 31, 2026. The award supports the development and testing of a novel fully-polymeric mitral valve constructed from a patented fluoropolymer formulation designed to combine the beneficial characteristics of both biologic and mechanical heart...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,024,635 project grant to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and enhance quality of life for heart failure patients by eliminating the need for a percutaneous driveline and external power supply. The key innovation is a hybrid magnetically levitated blood pump that requires...
- This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
- Federal Project Grant Award Summary The University of Texas at Austin received a $1,356,922 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 5, 2025, with completion targeted for May 31, 2029. This award funds the development and optimization of novel hydrogel-coated electrospun (HES) biomaterials designed for replacement heart valve (RHV) leaflets. The project addresses the critical clinical...
- Federal Project Grant Summary Northwestern University received a $150,104 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2025, with completion targeted for September 14, 2027. The research focuses on developing tissue engineered vascular grafts (TEVGs) resistant to calcification using matrix metalloprotease-degradable polyethylene glycol (MMP-PEG) hydrogels. The project aims to...
- This Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) supports research that studies how tissues modify their structure over time and how these changes are influenced by mechanical loading, with a focus on the aortic valve leaflet. The $649,992 award to the University of Wisconsin-Madison is for a 5-year project period from September 1, 2025 to August 31, 2030. The research aims to: 1) develop a new method to measure how the material properties...
LOW PROFILE TRANSCATHETER AORTIC VALVE IMPLANT - ABSTRACT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IS GRADUALLY BECOMING AN ESSENTIAL ALTERNATIVE TO SURGICAL AORTIC VALVE REPLACEMENT (SAVR) FOR PATIENTS WITH SEVERE AORTIC STENOSIS (AS) AT HIGH OR PROHIBITIVE SURGICAL RISK. THE PUBLISHED PARTNER 3 AND EVOLUT LOW-RISK TRIALS HAVE RECENTLY DEMONSTRATED THAT TAVR CAN BE CONSIDERED IN LOW-RISK PATIENTS. HOWEVER, THE LONG-TERM DURABILITY OF TRANSCATHETER PROSTHETIC VALVES HAS BECOME A MAJOR CONCERN NOWADAYS, ESPECIALLY FOR YOUNG PATIENTS WITH GREATER LIFE EXPECTANCY. ALTHOUGH INCREASED EFFICACY AND SAFETY OF THE CURRENT LEADING TAVR VALVES (E.G., MEDTRONIC COREVALVE AND EDWARDS SAPIEN) HAVE BEEN REPORTED LATELY, TISSUE VALVE DYSFUNCTION AND FAILURE REMAIN THE LIMITING FACTORS FOR THE LONG-TERM OUTCOME OF TAVR. FURTHERMORE, THE APPLICATION OF THOSE TAVR VALVES IS LIMITED TO CERTAIN PATIENTS DUE TO THE USE OF THE RELATIVELY LARGE DELIVERY SYSTEM (TYPICALLY 14-16 FR. SIZE). THERE IS A SUBSTANTIAL CLINICAL DESIRE FOR A LOWER-PROFILE DELIVERY SYSTEM SINCE IT ACCOMMODATES A GREATER POPULATION OF PATIENTS WITH PERIPHERAL ARTERY DISEASE OR SMALL ARTERIES AND REDUCES THE RISK OF VASCULAR COMPLICATIONS FOLLOWING TRANSFEMORAL TAVR. IT IS WELL KNOWN THAT CALCIFICATION PLAYS A MAJOR ROLE IN THE FAILURE OF BIOPROSTHESES AND OTHER TISSUE HEART VALVE SUBSTITUTES. MECHANICAL STRESS IMPOSED ON THE LEAFLETS CONTRIBUTES TO THE GROWTH OF CALCIUM CRYSTALS AND COLLAGEN FIBERS' DISRUPTION, WHICH INDUCES THROMBOSIS, CALCIFICATION, AND EARLY VALVE FAILURE. THEREFORE, A SUPERIOR BIOMATERIAL WITH APPROPRIATE MECHANICAL (LOW STRESS) AND STRUCTURAL (THICKNESS) PROPERTIES MAY PROVIDE A SOLUTION FOR PROLONGATION OF TRANSCATHETER VALVE DURABILITY AND SIZE REDUCTION OF DELIVERY SYSTEM. OUR GROUP HAS PREVIOUSLY VERIFIED THAT SWINE AND BOVINE PULMONARY VISCERAL PLEURA (PVP) ARE HIGHLY ELASTIC AND MUCH THINNER (~1/3 OF THE THICKNESS) THAN BOVINE PERICARDIAL TISSUE TYPICALLY USED FOR THE CURRENT TAVR VALVES. THE LARGER COMPLIANCE AND SMALLER THICKNESS OF PVP MAKE IT POSSIBLE TO BECOME A MORE DURABLE VALVE LEAFLET AND TO BE DELIVERED WITH A LOWER PROFILE DELIVERY SYSTEM (
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $497.4k | 4/15/24 |